Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02146924 · ClinicalTrials.gov registry record · Phase 1

Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

A Phase 1 study of Refractory Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
71
Enrollment target
1
Study location

NCT02146924 is a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 71 participants, above the 41-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (73% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02146924, a Phase 1 study of Refractory Acute Lymphoblastic Leukemia and B Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Conditions Studied

Refractory Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia Recurrent Acute Lymphoblastic Leukemia

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • BIOLOGICAL CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2014-10-16
Est. Completion 2026-07-15
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02146924

The ClinicalTrials.gov registry entry for NCT02146924 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 21 other Refractory Acute Lymphoblastic Leukemia trials with a reported enrollment target (73% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Refractory Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02146924 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02146924 about?

NCT02146924 is a clinical study titled "Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia". This phase I trial studies the side effects and best dose of cellular immunotherapy in treating patients with high-risk acute lymphoblastic leukemia. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

What is the current status of trial NCT02146924?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2014-10-16. Estimated completion is 2026-07-15.

What conditions does trial NCT02146924 study?

This clinical trial studies the following conditions: Refractory Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT02146924?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (BIOLOGICAL), CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (BIOLOGICAL).

Who is sponsoring clinical trial NCT02146924?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02146924 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Acute Lymphoblastic Leukemia

All registered trials for this condition

B Acute Lymphoblastic Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.